Illumina, Inc. (NASDAQ:ILMN) Director A Blaine Bowman sold 3,000 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $230.82, for a total transaction of $692,460.00. Following the sale, the director now owns 19,868 shares of the company’s stock, valued at $4,585,931.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Illumina, Inc. (ILMN) opened at $221.20 on Thursday. Illumina, Inc. has a one year low of $158.02 and a one year high of $248.97. The stock has a market cap of $32,236.80, a PE ratio of 44.60, a P/E/G ratio of 2.92 and a beta of 0.92. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.22. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The company had revenue of $778.00 million during the quarter, compared to the consensus estimate of $752.04 million. During the same period in the prior year, the firm earned $0.85 earnings per share. Illumina’s revenue was up 25.7% on a year-over-year basis. analysts anticipate that Illumina, Inc. will post 4.59 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. SeaCrest Wealth Management LLC bought a new position in Illumina in the fourth quarter worth about $154,000. Dupont Capital Management Corp bought a new position in Illumina in the third quarter worth about $153,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Illumina by 113.9% in the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after buying an additional 410 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 89 shares in the last quarter. Finally, Riverbridge Partners LLC bought a new position in shares of Illumina during the fourth quarter valued at approximately $202,000. 92.09% of the stock is owned by institutional investors.

Several research firms have issued reports on ILMN. First Analysis upgraded shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $277.00 price target for the company in a research report on Wednesday, January 31st. Canaccord Genuity restated a “buy” rating and set a $265.00 price target (up from $255.00) on shares of Illumina in a research report on Wednesday, January 31st. BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. Barclays increased their target price on shares of Illumina from $200.00 to $215.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 31st. Finally, Citigroup upgraded shares of Illumina from a “neutral” rating to a “buy” rating and increased their target price for the stock from $260.00 to $275.00 in a report on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the stock. Illumina presently has an average rating of “Buy” and an average target price of $241.39.

WARNING: “Illumina, Inc. (ILMN) Director Sells $692,460.00 in Stock” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/08/illumina-inc-ilmn-director-sells-692460-00-in-stock.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.